Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 11 -20 of 155 Show results per page	View Search Criteria \| Help With Results

First Published: 7/18/2008


11.		Phase III Randomized Study of PET/CT Scan-Guided Watchful Waiting Versus Planned Neck Dissection of Locally Advanced Nodal Metastases in Patients Undergoing Chemoradiotherapy For Primary Head and Neck Squamous Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Diagnostic, Treatment				Active				18 and over				Other				WMS-PET-NECK WMS-PET-NECK, ISRCTN13735240, EU-20856, MREC-07/Q1604/35, UKCRN ID: 3799, NCT00720070


12.		TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other				TTCC-2007-01 NCT00716391


13.		Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 70				Other				Eudract-2005-003911-63 PEI 119/01, NCT00311857


14.		Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				cpblb1-HMO-CTIL NCT00353717

Last Modified: 10/1/2008 First Published: 10/24/2006


15.		Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Gastrointestinal, Head and Neck, Non-Small Cell Lung, or Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				VU-VICC-GI-0622 VICC-GI-0622, 6980, NCI-6980, NCT00397384

First Published: 1/16/2007


16.		Phase I/II Study of Neoadjuvant Therapy Comprising Cetuximab, Oxaliplatin, Fluorouracil, and Radiotherapy in Patients With Stage II or III Squamous Cell Carcinoma of the Esophagus

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 70				Other				KRDI-TUM-OE7-432-LOR-0033-I EU-20658, EUDRACT-2006-001097-24, NCT00425425

Last Modified: 9/30/2008 First Published: 12/1/2006


17.		Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Solid Tumors or Progressive or Recurrent Stage III or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				UCDCC-177 BMS-4608, BMS-CA225-261, NCT00408499

Last Modified: 3/7/2007 First Published: 2/21/2007


18.		Phase I/II Study of Neoadjuvant Cetuximab, Docetaxel, and Cisplatin in Combination With Radiotherapy in Patients With Resectable Locally Advanced Esophageal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 70				Other				SWS-SAKK-75/06 EU-20702, NCT00445861


19.		Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				TUD-COFI-014 NCT00422773


20.		Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Pharmaceutical / Industry				UCIRB #14735B GV-001.010 (TNF-ELF), NCT00496236

Select All on One Page


					< Previous 1 2 3 4 5 Next >

| | | | | | | |

A Service of the National Cancer Institute